HomeSLNCF • OTCMKTS
add
Silence Therapeutics plc
Previous close
$7.00
Year range
$0.60 - $10.90
Market cap
1.07B USD
Avg Volume
113.00
P/E ratio
-
Dividend yield
-
Primary exchange
OTCMKTS
In the news
Financials
Income Statement
Revenue
Net income
| (GBP) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 12.41M | 9.07% |
Operating expense | 14.35M | -24.44% |
Net income | -1.88M | 81.62% |
Net profit margin | -15.12 | 83.15% |
Earnings per share | -0.05 | 85.05% |
EBITDA | -4.07M | 66.10% |
Effective tax rate | 44.25% | — |
Balance Sheet
Total assets
Total liabilities
| (GBP) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 152.75M | 142.98% |
Total assets | 194.38M | 106.05% |
Total liabilities | 70.48M | -9.35% |
Total equity | 123.90M | — |
Shares outstanding | 44.67M | — |
Price to book | 2.53 | — |
Return on assets | -7.21% | — |
Return on capital | -14.69% | — |
Cash Flow
Net change in cash
| (GBP) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -1.88M | 81.62% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Silence Therapeutics, is a London-based pharmaceutical company formed in 1994. The company since its inception has pioneered the design and development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London. Wikipedia
Founded
1994
Website
Employees
109
